SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Zogenix, Inc.
NEW YORK, NY / ACCESSWIRE / April 8, 2019 / Levi & Korsinsky announces it has commenced an investigation of Zogenix, Inc. (''Zogenix'' or ''the Company'') (ZGNX) concerning possible violations of federal securities laws.
On April 8, 2019, Zogenix issued a press release announcing the receipt of a Refusal to File (RTF) letter from the U.S. Food and Drug Administration regarding its New Drug Application for FINTEPLA. According to Zogenix, the FDA determined that the NDA ''was not sufficiently complete to permit a substantive review.'' To obtain additional information, go to:
https://www.zlk.com/pslra-1/zogenix-inc-loss-form
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York,NY 10006
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/541386/SHAREHOLDER-ALERT-Levi-Korsinsky-LLP-Notifies-Investors-of-an-Investigation-Involving-Possible-Securities-Fraud-Violations-by-Certain-Officers-and-Directors-of-Zogenix-Inc
